Read on Twitter
#AVCT 
Avacta today announce the initial global diagnostic manufacturing partner for their lateral flow test
BBI has a global reach, 5 manufacturing hubs in 5 different countries, spanning 4 continents.
This means BBI will use a diversified approach to ensure...
Avacta today announce the initial global diagnostic manufacturing partner for their lateral flow test
BBI has a global reach, 5 manufacturing hubs in 5 different countries, spanning 4 continents.
This means BBI will use a diversified approach to ensure...
#AVCT
...manufacturing logistics in conjunction with our distributor Medusa 19 can be as fast and efficient as possible
Secondly, this also is confirmation that optimisation has reached a significant milestone, something which I believe Avacta and Cytiva are confident....
...manufacturing logistics in conjunction with our distributor Medusa 19 can be as fast and efficient as possible
Secondly, this also is confirmation that optimisation has reached a significant milestone, something which I believe Avacta and Cytiva are confident....
#AVCT
...will pass clinical validations for regulatory approval and mass distribution
I also believe optimisation will continue to try to obtain an even higher specificity and sensitivity in the battle to create the best global test in LFT 2.0 which I think will be...
...will pass clinical validations for regulatory approval and mass distribution
I also believe optimisation will continue to try to obtain an even higher specificity and sensitivity in the battle to create the best global test in LFT 2.0 which I think will be...
#AVCT
...created end of this year (First LFT to market Mid Sept)
Another VERY STRONG validation that Affimer technology is world class?
RNS states test is STILL saliva based.
SONA’s Test was previously Saliva but due to difficulties they had to change to Nasopharyngeal...
...created end of this year (First LFT to market Mid Sept)
Another VERY STRONG validation that Affimer technology is world class?
RNS states test is STILL saliva based.
SONA’s Test was previously Saliva but due to difficulties they had to change to Nasopharyngeal...
#AVCT
This signifies Avacta’s Affimers are superior and potentially is HUGE validation for the whole Affimer concept
If they do prove to be much better than monoclonal antibodies and it’s similar peers this paves the way for a market share in the antibody market to be...
This signifies Avacta’s Affimers are superior and potentially is HUGE validation for the whole Affimer concept
If they do prove to be much better than monoclonal antibodies and it’s similar peers this paves the way for a market share in the antibody market to be...
#AVCT
... huge, potentially in excess of £20bn MCap
... huge, potentially in excess of £20bn MCap
#AVCT
If Avacta is only one of the few saliva based LFT’s to reach market
I believe schemes such as
CONDOR
and RADx NIH
will significantly assist and provide the logistical partners (Major Pharma such as GSK, AstraZeneca and Roche)
To partner to scale up these tests
If Avacta is only one of the few saliva based LFT’s to reach market
I believe schemes such as
CONDOR
and RADx NIH will significantly assist and provide the logistical partners (Major Pharma such as GSK, AstraZeneca and Roche)To partner to scale up these tests
#AVCT
Highlighting Alastair’s comments
-additional manufacturing partners will be enrolled
-sharing my thoughts also that testing requirement will be needed for new few years(IMO likely to be 2-3 years atleast)
-expansion of production fac as the demand for reagents HUGE
Highlighting Alastair’s comments
-additional manufacturing partners will be enrolled
-sharing my thoughts also that testing requirement will be needed for new few years(IMO likely to be 2-3 years atleast)
-expansion of production fac as the demand for reagents HUGE
